Physician profile
Jane Berger
NPI 1285906883
$4,484.69
in general payments reported to CMS, 2019-2025
31 companies · $762 in 2025
The $762 reported for 2025 was more than what 82% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,135 · 2022: $1,206 · 2023: $657 · 2024: $725 · 2025: $762.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,144.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,143.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $636.91 | 2021-2025 | Wegovy, Saxenda, Ozempic |
| Lilly USA, LLC | $569.01 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbvie INC. | $397.53 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $326.80 | 2021-2024 | Jardiance |
| Glaxosmithkline, LLC. | $208.59 | 2021-2025 | Bexsero, Shingrix, Arexvy |
| Pfizer INC. | $200.11 | 2023-2025 | |
| Exact Sciences Corporation | $190.67 | 2025 | The Cologuard Plus Collection Kit |
| Hologic Sales and Service, LLC | $181.15 | 2021-2025 | Aptima |
| Biohaven Pharmaceutical Holding Company LTD. | $178.45 | 2022 | |
| Alk-Abello, INC | $145.91 | 2024-2025 | Odactra, Grastek, Neffy |
| Amgen INC. | $140.69 | 2023-2025 | Repatha, Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $131.40 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $123.26 | 2021-2023 | Rotateq, Vaxelis, Vaxneuvance |
| Gilead Sciences, INC. | $122.64 | 2021-2022 | |
| Cranial Technologies, INC | $120.41 | 2021-2025 | Doc Band |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $118.40 | 2021-2025 | Dexcom G6 Transmitter |
| Becton, Dickinson and Company | $114.42 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $87.13 | 2022-2024 | Breztri, Farxiga |
| Biohaven Pharmaceuticals, INC. | $82.74 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $81.96 | 2024 | Xifaxan |
| Janssen Pharmaceuticals, INC | $61.66 | 2023-2024 | Spravato |
| Vbi Vaccine (Delaware) INC. | $50.39 | 2022 | |
| Astellas Pharma US INC | $49.94 | 2024-2025 | Veozah |
| Qiagen, LLC | $43.78 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $20.61 | 2025 | |
| Phadia US INC. | $20.51 | 2024 | Immunocap |
| Sanofi Pasteur INC. | $17.37 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $16.69 | 2022 | |
| Scilex Pharmaceuticals INC. | $15.89 | 2022 | |
| Amarin Pharma, INC. | $15.78 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.89 | 2025 | Zoryve |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Berger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.